TLN2 and breast carcinoma: In breast cancer, miR-194-5p is specially induced by trastuzumab, a humanized murine anti-HER2 monoclonal antibody, and inhibits invasion and migration of HER2-overexpressing breast cancer cells by targeting Talin 2 [41].